
Status Epilepticus Pathway



Refractory Status Epilepticus Pathway

SUPPORTIVE CARE

- Aggressively manage sources of secondary insult
- •Fever
- Hypotension
- Hypoxemia
- •Head of bed at 30° and midline
- Avoid hyponatremia, hypocalcemia, hypomagnesemia.
- Hourly neuro checks
- •Continuous EEG (double distance after 48 hours)
- If on baseline AEDs are available, correction to therapeutic range

Respiratory

- •Prophylactic intubation not indicated at lower versed infusion rates (≤0.4 mg/kg/hr)
- •Monitor closely for impaired airway protection/ability to clear secretions
- •Empiric intubation if goal EEG= burst suppression
- •Maintain PaCO₂ 35-40 mmHg


Cardiovascular

- Versed and pentobarbital result in lowered SVR and depressed cardiac output
- •Place arterial line if goal EEG= burst suppression or versed infusion rate ≥ 0.4 mg/kg/hr
- •Maintain MAPs at 50% ile for age
- •Fluid bolus 20 mg/kg x2
- If still hypotensive
- Dopamine 5-15 mcg/kg/min then
- Epinephrine 0.1 mcg/kg/min if poor perfusion or
- Norepinephrine 0.1 mcg/kg/min if well perfused

FEN/GI

- •IVF fluids—1st 48 hrs
- Normal Saline
- Add D5 if:
 - serum glucose < 80 mg/dL
- •Age <6 mos
- •Accu check glucose q 4-6 hrs while on IVF
- •After 48 hrs consider TPN or enteral feeds
- •Recommend TPN for patients in burst suppression
- •Goal fluid balance 0 to +10 ml/kg/d
- •Consider GI prophylaxis

Continued on next page



Refractory Status Epilepticus Pathway

Supportive Care (cont)

ID

- Refer to Acute Encephalopathy Algorithm if suspected infectious/inflammatory etiology
- Minimize risk for nosocomial infections
- Daily assessment for need of foley or central access
- · Standard precautions against VAP
- Absolute indications for central access:
 - + inotropic medications
 - + TPN
- •+ goal EEG= Burst Suppression
- Relative indications for central access:
 - · Frequent lab draws
 - Difficulty obtaining peripheral IV acess
 - Versed infusion ≥ 0.4 mg/kg/hr

Heme


•DVT prophylaxis w/ venodynes if past puberty

Musculoskeletal/Skin


- Specialty care bed and close monitoring for decubitus ulcers
- Physical therapy consult for splints and range of motion exercises

ORDER pentobarbital infusion to achieve seizure cessation

- •Discontinue versed infusion
- •Order bolus of 10 mg/kg of pentobarbital. Give first 5 mg/kg over 15 minutes. Bolus additional 5 mg/kg over 15 minutes.
- •If no burst suppression with interburst interval (IBI) of 5-7 seconds after first pentobarbital bolus.
 - Repeat boluses should **immediately** follow prior bolus until burst suppression is achieved
- •Place order requesting bedside RN to notify MD prior to end of bolus infusion to review EEG pattern
- •Review EEG q 15 min until burst suppression achieved
- •Once burst suppressed, start infusion at 1 mg/kg/hr
- •Consider immune modulating therapies (e.g. IVIG)
- •Titrate pentobarbital infusion to maintain BS with IBI of 5-7 seconds
- •Increase infusion by 0.5 mg/kg/hr (max 3 mg/kg/hr) if IBI < 5 sec or seizure
- •If IBI becomes too long, hold infusion until IBI is <20s, then resume infusion at dose 0.5 mg/kg/hr less than previous dose
- •Continue burst suppression for minimum of 24 hrs
- Wean no faster than 0.5 mg/kg every 6hrs



Refractory Status Epilepticus Pathway



Status Epilepticus Timeline

| Time | Intervention Category | Specific Intervention |
|----------------|--------------------------|--|
| 0-5 minutes | Monitoring | Clinical recognition of seizure |
| | Therapeutic | LORazepam 0.1 mg/kg (max 4 mg/dose) IV, may repeat X 1 for ongoing seizure (midazolam 0.2 mg/kg, max 10 mg IV/IM is equivalent) ORDER fosphenytoin 20 mgPE/kg (max 1500mg/dose) IV/IM upon administration of 2 nd LORazepam dose independent of seizure cessation |
| | Diagnostic | r/o hypoglycemia or electrolyte disturbance AED levels if on chronic AEDs |
| | Goal | Complete cessation of Seizure |
| | Co | ontinued encephalopathy or concern for clinical seizures |
| 5-30 minutes | Monitoring | Clinical monitoring Look for small clonic movements, vital sign changes (e.g. hypertension and tachycardia) suggestive of ongoing seizure Assess for fever and airway protection |
| | Therapeutic | Verify fosphenytoin dose was received ORDER PHENobarbital 20 mg/kg (max 1000 mg/dose) IV If on chronic phenytoin or PHENobarbital will need to modify |
| | Diagnostic | CT scan if new onset seizure or if patient has VP shunt LP if fever or new onset seizure (exclude if hx of febrile seizure) Obtain 10-20 ml CSF Begin empiric IV acyclovir and antibiotics for possible meningitis ORDER EEG and call x7962 (EEG techs) for placement in ICU or ED if PICU bed not readily available |
| | Goal | Cessation of seizure |
| (| Continued encepha | lopathy (not explained by post-ictal state) or concern for clinical seizures |
| 30-60 minutes | Monitoring | Clinical monitoring Consult Neurology Transfer to PICU Continuous EEG placed upon transfer to ICU (coordinate with imaging, if image delay monitor EEG with double distance lead placement) |
| | Therapeutic | PHENobarbital dose was received, consider additional 10 mg/kg bolus (max 1000 mg) of PHENobarbital Midazolam bolus 0.2 mg/kg (max 10mg/dose) followed by continuous infusion of 0.1 mg/kg/hr Bolus midazolam until infusion arrives If inadequate seizure control, titrate midazolam infusion every 15-30 minutes Bolus new hourly rate every other titration See RSE pathway for more details |
| | Diagnostic | See Encephalitis/Encephalopathy Pathway Metabolic work up |
| | Goal | Seizure cessation |

| Continued encephalopathy or concern for clinical seizures | | | | |
|---|-------------|--|--|--|
| 1-3 hours | Monitoring | Continuous EEG in place | | |
| | | Monitor for hypotension – consider central access | | |
| | Therapeutic | Titration of midazolam continuous infusion every 15-30 minutes | | |
| | | Bolus new hourly rate every other titration | | |
| | D: | See RSE pathway for more details | | |
| | Diagnostic | MRI once seizures controlled | | |
| | | AED levels if bolus provided earlier | | |
| | C1 | Follow up with EEG for read | | |
| | Goal | Seizure cessation (100% clinical and electrographic) Consider burst suppression | | |
| | | | | |
| 3- 12 | Monitoring | Continuous EEG in place | | |
| hours | | Monitor for hypotension and respiratory failure | | |
| | Therapeutic | If seizure control: maintain infusion | | |
| | 1 | If no seizure control: continue to rapidly increase midazolam infusion to maximum | | |
| | | 2 mg/kg/hr (refer to pathway for more details) | | |
| | | Consider other AED options | | |
| | Diagnostic | ID Consult if concern for encephalitis, f/u on labs and LP | | |
| | Goal | Seizure cessation or transition off midazolam to 2 nd agent | | |
| | • | | | |
| 12-24 | Monitoring | Continuous EEG | | |
| hours | S | | | |
| | Therapeutic | If seizure control: maintain midazolam infusion for additional 24 hours | | |
| | | If no or poor seizure control: discontinue midazolam infusion and start PENTobar- | | |
| | | bital, propofol or ketamine infusion (refer to pathway for more details). | | |
| | | DENTohambital Dalva 10 ma/ka à Civa first 5 ma/ka aven 15 minutes halva addi | | |
| | | PENTobarbital : Bolus 10 mg/kg à Give first 5 mg/kg over 15 minutes, bolus additional 5 mg/kg over 15 minutes. If no burst suppression with IBI of 5-7 seconds | | |
| | | repeat boluses should immediately follow until burst suppression is achieved. | | |
| | | Start maintenance at 1-3 mg/kg/hr. | | |
| | | Adv: historical first line agent | | |
| | | Disadv: hypotension, ileus, increased infection risk, drug interactions | | |
| | | 2 is a way in the second of th | | |
| | | Propofol : 3-5 mg/ kg load, maintenance at 75-150 mcg/kg/min | | |
| | | Adv: fewer drug interactions | | |
| | | Disadv: hypotension, prolonged use associated with propofol infusion syn- | | |
| | | drome | | |
| | | CONTRAINDICATED in patients on ketogenic diet, if concern for metabolic | | |
| | | disorder (especially mitochondrial disorder), egg allergy | | |
| | | Ketamine : 1-3 mg/kg load, maintenance at 2-5 mg/kg/hr | | |
| | | Adv: less hemodynamic compromise, non-GABA mechanism of action, fewer | | |
| | | drug interactions | | |
| | | Disadv: potential neurotoxin, newer agent | | |
| | Diagnostic | f/u ID consult, LP results, and EEG read | | |
| | | Call lab and request storage of CSF for 14 days | | |
| | | Consideration of autoimmune/paraneoplastic process | | |
| | Goal | Seizure cessation or titration of 2 nd agent | | |
| | | Normal hemodynamics, monitor for infections, consider nutritional support | | |

| 48 hours | Monitoring | Continuous EEG |
|--------------|-------------|---|
| | | Monitor skin carefully for breakdown/irritation |
| | Therapeutic | Once seizures are under control for 48hrs, begin to wean (per protocol) |
| | | If poor control: optimize current drip to ensure burst suppression |
| | | Consider IVIG for non-epilepsy patients, refer to encephalitis pathway |
| | Diagnostic | Completion of ID work up/autoimmune work up |
| | | Call outside labs to confirm receipt |
| | Goal | Titration to burst suppression for duration of 48 hours |
| | | If Seizures return upon weaning |
| >48 | Monitoring | Continuous EEG |
| hours | | Monitor skin carefully for breakdown/irritation (consider double distance lead placement) |
| | Therapeutic | Consider slower wean (q12 instead of q6/q8 or q24 instead of q12) |
| | 1 | Consider change in general anesthetic approach |
| | | Consider manipulation of chronic AEDs (valproic, phenobarb, topiramate, |
| | | fosphenytoin) |
| | | Consider methylprednisolone 30 mg/kg (max 1 gm/dose) IV daily x 3 days, then 1 |
| | | mg/kg IV daily for 4 days (continue if + response) |
| | | Determine acyclovir course |
| | Diagnostic | Consider repeat MRI (with contrast) |
| | | Consider repeat LP, discuss with ID |
| | Goal | Seizure cessation or transition to 3 rd continuous infusion for 48 hours of burst sup- |
| | | pression |
| | Other | Family Meeting with Neurology and CCM if return of epileptic activity at time |
| | | weaning |
| | | Continued seizures |
| >5-7 days | Monitoring | Consider EEG break |
| | Therapeutic | Consider nutritional support unless preexisting malnutrition |
| | | Consider: |
| | | Plasma exchange |
| | | Hypothermia |
| | | Ketogenic diet |
| | | Inhaled Anesthetics |
| | Diagnostic | Consider brain biopsy |
| | | |

FIRES Management

FIRES criteria

SRSE (must have failed wean of 3rd line agent)

Age 3-17

Seizures preceded by febrile illness

No alternative diagnosis despite comprehensive evaluation for infectious and inflammatory causes of seizures

Strategies for weaning infusion medications

Phenobarbital with goal levels ~ 100

Felbamate with goal levels > 50 (fosphenytoin drives level down)

Avoid propofol (due to concerns for secondary mitochondrial injury and propofol infusion syndrome)

Start metabolic supplements (see page 8)

Start ketogenic diet

Start aggressive bowel regimen (if being fed enterally).

* ILEUS IS NOT COMPATIBLE WITH ENTERAL AED ADMINISTRATION

Attend to parental inquiries regarding cannabadiols.

Bolus ketamine 1 mg/kg and begin infusion 1 mg/kg/hr (titrate to max of 10 mg/kg/hr)

Avoid polypharmacy, limit background AEDs to 4

Strategies for reducing inflammation

Begin pulse dose steroids (see page 8 for dosing)

Begin IVIG 2g/kg div 2 days as soon as labs sent (must confirm they are received in the lab and being processed)

Begin Anakinra (5 mg/kg/dose BID) once FIRES suspected

Consider PLEX if hemodynamically stable (will need to get AED labs post PLEX and bolus immediately after infusion) - anticipate timing for line placement and transfusion team preparation.

Consider Cytoxan if seizures continue to be refractory beyond week 3

Monitoring

Switch EEG to double distance once burst suppressed

Scalp breaks should be given every 4 days (minimum 4 hours)

Daily am trough for AED levels (phenobarbital, phenytoin, VPA)

Felbamate and Topiramate levels Monday and Thursday

High index of suspicion for DRESS (monitor for rash), HLH (multiorgan failure, increased TG and ferritin), dysautonomia (including gut dysmotility)

MRI brain every 2-4 weeks during initial PICU admission